Clinical Trial Finder

Inclusion Criteria:

• - Patient has an established diagnosis of ulcerative colitis for at least 3 months prior to Screening.

• - Patient has active mild to moderate ulcerative colitis at Visit 2.

• - Patient is taking at least one of the following oral medication: 5-ASA, Corticosteroids, Immunomodulators.

Exclusion Criteria:

• - Patient has a possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory bowel disorders.

• - Patient has a persistent fever of ≥ 38.3°C.

• - Patient has current signs or symptoms of infection.

• - Patient has any immunosuppressant condition.

• - Patient has a known malignancy within 5 years prior to Screening.

• - Patient who has a medical history of drug abuse or alcohol abuse.

• - Patient who, in the opinion of the Investigator, has a clinically significant co-morbid disease.

• - Patient has hepatic failure.

• - Patient is pregnant or plans a pregnancy within the study period.

• - Patient has no previous history of treatment for ulcerative colitis (treatment-naïve patient) - Patient has ongoing or failed treatment for ulcerative colitis with calcineurin inhibitor.

• - Patient has received biologic medication.

• - Patient has received antibiotics within 4 weeks prior to Visit 2.

• - Patient is unable to stop previous antibiotics treatment during study period.

• - Patient has received probiotics within 2 weeks prior to Visit 2.

• - Patient with history of major surgery in any region of the gastrointestinal tract.

• - Patient has received any investigational product or participated in another clinical trial.

• - Patient has a stool culture or other examination positive for an enteric pathogen.

• - Patient tests positive for CMV by PCR test at Screening.

• - Patient tests positive for HIV at Screening.

• - Exclusion criteria based on results of Hepatitis B at Screening.

- Exclusion criteria based on results of Hepatitis C at Screening

Arms

Placebo Comparator: Placebo

3 capsules twice a day dosing of Placebo

Experimental: KBL697

3 capsules twice a day dosing of KBL697

Interventions

Drug: - KBL697

3 capsules twice a day dosing of KBL697

Drug: - Placebo

3 capsules twice a day dosing of Placebo